OTCMKTS:EPGNY Epigenomics (EPGNY) Stock Price, News & Analysis $2.39 0.00 (0.00%) As of 04/6/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Epigenomics Stock (OTCMKTS:EPGNY) Get Epigenomics alerts:Sign Up Key Stats Today's Range$2.39▼$2.3950-Day Range$2.39▼$2.3952-Week Range$2.01▼$2.39VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Epigenomics AG (OTCMKTS: EPGNY) is a molecular diagnostics company focused on the discovery, development and commercialization of epigenetic biomarker assays for early cancer detection. The company’s proprietary technology platform analyzes DNA methylation patterns in circulating cell‐free DNA, aiming to identify and differentiate malignant from benign conditions. Epigenomics’ approach seeks to provide non-invasive, blood-based screening tests that can complement or replace existing methods such as colonoscopy or imaging in certain settings. The company’s lead diagnostic test, Epi proColon, is a CE-IVD marked blood test for colorectal cancer screening in Europe and was granted FDA approval in the United States in 2016. By targeting a specific methylated gene marker associated with colorectal tumors, Epi proColon offers an alternative for individuals who are reluctant or unable to undergo conventional screening procedures. Beyond its flagship product, Epigenomics is advancing a pipeline of assays for other solid tumors—including lung and pancreatic cancer—through collaborations with academic institutions and industry partners to validate novel methylation signatures. Founded in 1998 and headquartered in Berlin, Germany, Epigenomics has established a commercial presence in both Europe and North America, with distribution agreements extending into Asia. The company’s leadership team brings together expertise in molecular biology, diagnostics development and regulatory affairs to drive product innovation and market access. Epigenomics continues to invest in research partnerships and clinical studies aimed at expanding the clinical utility of its platform across a broader range of oncology indications.AI Generated. May Contain Errors. Read More Receive EPGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPGNY Stock News HeadlinesEQS-News: Epigenomics AG publishes financial results for fiscal year 2023March 14, 2024 | markets.businessinsider.comEQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive BoardJanuary 31, 2024 | markets.businessinsider.comQuiet Tickers. Strong Signals. Here’s What’s Brewing…The final stretch of the year is packed with uncertainty — but while others guess, smart traders focus on verified market activity. Our free Small-Cap Signals Guide shows how to spot early momentum shifts, identify small caps with breakout potential, and understand the setups analysts are watching now. | Market Crux (Ad)EQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comCardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in EpigenomicsSeptember 20, 2023 | finance.yahoo.comNew Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General MeetingSeptember 14, 2023 | benzinga.comEQS-News: Epigenomics AG publishes financial results for the first six months 2023August 10, 2023 | markets.businessinsider.comSee More Headlines EPGNY Stock Analysis - Frequently Asked Questions How have EPGNY shares performed this year? Epigenomics' stock was trading at $2.39 at the beginning of 2025. Since then, EPGNY shares have increased by 0.0% and is now trading at $2.39. How do I buy shares of Epigenomics? Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolOTCMKTS:EPGNY CIKN/A Webwww.epigenomics.com Phone(493) 024-3450FaxN/AEmployees32Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:EPGNY) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epigenomics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Epigenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.